Vice President and Head, Translational Sciences and Clinical Biomarkers @ (January 2022 - May 2025)
Senior Director Translational Medicine @ (June 2020 - January 2022)
Senior Director Experimental Medicine Unit @ TESARO/GSK (January 2020 - June 2020)
Senior Director Immuno-Oncology Translational Research and Development @ TESARO, Inc. (February 2018 - January 2020)
Director Translational and Biomarker Research @ Takeda Pharmaceuticals International Co. (September 2016 - February 2018)
Associate Director @ (March 2014 - August 2016)
Senior Scientist I @ (October 2011 - January 2014)
Scientist II @ (January 2007 - January 2011)
Scientist @ (September 2005 - January 2008)
Post Doc @
Hadi Danaee Education
Harvard School of Public Health
SD (Cancer Biology)
1998-2004
The University of Connecticut
BSc (Molecular and Cellular Biology)
1988-1992
Brookline High School
High School
1984-1988
Hadi Danaee Skills
Oncology
Translational Medicine
Biomarkers
Assay Development
Cancer
Drug Development
Drug Discovery
Clinical Trials
Clinical Development
Genotyping
Clinical Research
Biotechnology
Biomarker Discovery
In Vitro
Pharmaceutical Industry
Biomarker Development
Pharmaceuticals
companion diagnostics
Outsourcing
Life Sciences
Cell Biology
Immunohistochemistry
Immunofluorescence
Image Analysis
ADCs
Immuno oncology
Digital Pathology
Cancer Therapeutics
Microsoft Office
Development
Data Analysis
Microsoft Word
Leadership
Hadi Danaee Summary
Hadi Danaee, based in Boston, MA, US, is currently a Vice President, Translational Medicine at Puma Biotechnology, Inc.. Hadi Danaee brings experience from previous roles at NeoGenomics Laboratories, HotSpot Therapeutics, Inc., Blueprint Medicines and TESARO/GSK. Hadi Danaee holds a 1998 - 2004 SD in Cancer Biology @ Harvard School of Public Health. With a robust skill set that includes Oncology, Translational Medicine, Biomarkers, Assay Development, Cancer and more. Hadi Danaee has 2 emails and 1 mobile phone numbers on RocketReach.
Looking for a different Hadi Danaee?
Find contact details for 700 million professionals.